Rubicon Research IPO subscribed over 2.49x on day 2

Rubicon Research IPO subscription started on Thursday, October 9, 2025 and will close on October 13, 2025, as scheduled. The price band is set at ₹461 to ₹485 per share with a face value of ₹1.

Rubicon Research IPO Subscription Status

Rubicon Research IPO subscribed over 2.49x on its second day till 05.00 PM on October 10, 2025.

Rubicon Research IPO subscription QIB investors portion is 2.22x times, while NII subscribers subscribed 1.92x times, and RII investors subscribed 4.16x times.
The company has received bids for 3,89,64,540 shares against 1,56,37,349 shares on offer on the second day.
Rubicon Research IPO subscribed over 2.49x on day 2.
Rubicon Research IPO subscribed over 0.54x on day 1.

About Rubicon Research IPO

Rubicon Research is one of the leading pharmaceutical formulations companies and focuses on innovation through dedicated research and development. Moreover, their portfolio includes specialty products and drug-device combination products, aimed mainly at regulated markets, especially the United States.

Furthermore, they believe their multi-disciplinary, data-driven, and return on investment (“ROI”) centric product selection framework is geared towards identifying sustainable opportunities for new product development. Moreover, they find and go after opportunities that give an edge by using skills in development, manufacturing, and sales to grow market share.

The company has unique strengths, the Fastest-growing Indian pharmaceutical company compared to peers, a Data-driven way to choose products, a Strong research and development team, Solid sales and distribution network in the US.

Rubicon Research IPO GMP:

Rubicon Research IPO GMP was ₹100 as of Friday, October 10, 2025. That indicates the IPO is trading at ₹585 with a ₹100 premium in the grey market against the issue price of ₹485.

Vijay Prajapati

An experienced stock market professional with expertise in IPO research, market insights, and equity strategies. With a strong background in research and capital markets, he delivers comprehensive coverage on upcoming IPOs, subscription patterns, grey market premium (GMP), and post-listing performance, along with detailed reviews, recommendations, and technical analysis.

Add IPOWatch to your Google News feed.

Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations. The Investors are advised to do their own research or connect with a financial advisor before making any investment decisions.